Aterian Inc
2 nominees · 8 ballot items.
Eight proposals: (1) Approve sale of substantially all assets to Trademark Global; (2) Elect Avraham Ben-Tzi and David Natan as directors; (3) Approve issuance of Common Stock upon conversion of Series AA and Series AAA Preferred Stock (Change of Control); (4) Approve issuance of Common Stock upon conversion of Preferred Stock to a director (Related Party); (5) Approve issuance of shares upon conversion of Preferred Stock (Issuance); (6) Approve amendment to effect reverse stock split (1-for-2 to 1-for-99 range); (7) Approve amendment to increase authorized Common Stock up to 1,000,000,000; (8) Approve adjournment of the Special Meeting to solicit additional votes.
Follow how the vote landed and what changed on Aterian Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot8
- 1
Asset Sale Proposal
ManagementBoard: FORApprove sale of substantially all assets of the Company to Trademark Global, LLC pursuant to the Asset Purchase Agreement dated April 27, 2026 for $18,000,000 cash (subject to adjustments) and related terms.
- 2
Director Election Proposal
ManagementBoard: FORElect Avraham Ben-Tzi as Class II director and David Natan as Class III director to serve terms expiring 2027 and 2028, respectively.
- 3
Change of Control Proposal
ManagementBoard: FORApprove, under Nasdaq Listing Rule 5635(b), issuance of shares of Common Stock upon conversion of Series AA and Series AAA Preferred Stock issued to David E. Lazar in the Securities Purchase Agreement.
More detail
This proposal asks shareholders to approve, under Nasdaq Listing Rule 5635(b), the potential issuance of Common Stock upon conversion of the Series AA and Series AAA Preferred Stock sold to David E. Lazar. The transactions were negotiated as part of a Securities Purchase Agreement that raises $7.0 million in gross proceeds and contemplates conversion terms that would allow Lazar to acquire rights to a large number of Common Shares (up to a combined maximum of 249,909,030 Common Shares upon full conversion under currently disclosed conversion formulae) and therefore could effect a change of control. Management and the Board say the stockholder vote is required by Nasdaq rules because the issuance would enable a holder to own 20% or more of voting power and thus meet Nasdaq’s change-of-control threshold. The Board recommends approval, arguing the Investment Transaction brings capital and leadership needed to pursue a new strategic direction, reduces near-term leverage and positions the company to return cash from an asset sale and to pursue a post-investment transaction; it also stresses the interdependencies with other proposals (conversion-issuance approvals and charter amendments). Opposing considerations include: the substantial potential dilution to existing holders, complex anti-dilution mechanics and the risk that Lazar would hold effective voting control (and related Nasdaq “controlled company” exemptions may apply); the contingent mechanics that, if SPAs do not close, trigger alternate share issuances and the uncertainty over final conversion rates; and the governance risks associated with concentrated ownership and imminent management changes. A sophisticated analysis must weigh the immediate financing and operational runway against the prospect of near-total dilution and control transfer, the likely leverage of the financing to enable a post-closing strategic shift, and the fact that Nasdaq approval is a technical, rather than an economic, regulatory gate — i.e., stockholder approval does not itself limit future exercises of control following conversion.
- 4
Related Party Proposal
ManagementBoard: FORApprove, under Nasdaq Listing Rule 5635(c), issuance of shares of Common Stock upon conversion of Preferred Stock to a director (David E. Lazar) who will become Chairman and CEO following the Second SPA Closing.
More detail
This shareholder authorization addresses the transaction-specific Nasdaq rule that requires stockholder approval when a related party (here, a director who will become Chair and CEO) receives equity compensation or convertible securities at terms that could be viewed as discounted or raising control concerns. The Securities Purchase Agreement contemplates that certain Preferred Stock would convert into a substantial number of Common Shares and that Mr. Lazar — already a director and designated to receive significant Preferred stock — could, upon conversion, acquire a dominant ownership position. Management’s view is that approval is procedural and necessary to conform to Listing Rule 5635(c); it is contingent on the overall investment and governance package set out in the SPA. The board recommends approval on the grounds that the Investment Transaction supports the Company’s capital and strategic plans. A sophisticated analysis must weigh the technical Nasdaq compliance need against the economic effects: the transaction would materially dilute current holders and transfer decisive voting influence to Lazar; the board argues that the capital and management change are necessary to execute a post-transaction strategy; opponents will be concerned about entrenchment, related-party conflicts, structurally complex conversion mechanics and the potential for a “controlled company” outcome under Nasdaq rules.
- 5
Issuance Proposal
ManagementBoard: FORApprove, under Nasdaq Listing Rule 5635(d), issuance of shares of Common Stock upon conversion of the Preferred Stock where issuance would equal 19.99% or more of the outstanding shares prior to issuance at a price below certain thresholds.
More detail
This proposal seeks shareholder approval under Nasdaq Rule 5635(d) for the issuance of Common Stock upon conversion of the Preferred Stock sold to Lazar, because the conversion could result in issuance equal to 19.99% or more of the pre-issuance outstanding shares at an effective price below specified Nasdaq thresholds. If approved, the Company can proceed with conversion mechanics that are part of the Securities Purchase Agreement without violating Nasdaq rules. Management argues that the approval is necessary to implement the funding and strategic plan; the board recommends approval. From an analytical viewpoint, the proposal is a regulatory housekeeping measure with substantial economic consequences: the issuance would cause material dilution and likely transfer decisive voting power to Lazar. If approval is refused, the SPA contains fallback mechanics — a mandated issuance at market price giving Lazar up to 19.99% — that still dilute existing holders but limit full conversion; this safety valve reduces the practical leverage of a negative vote and means there is a credible alternative that reduces negotiation risk for investors. Any investor analysis must weigh the immediate financing value and execution risk against the loss of voting influence and potential “controlled company” status and resulting potential governance differences.
- 6
Reverse Stock Split Proposal
ManagementBoard: FORApprove amendment to the Certificate of Incorporation to permit the Board, at its discretion, to effect a reverse stock split of Common Stock at a ratio within 1-for-2 to 1-for-99.
More detail
This management proposal asks shareholders to authorize a Charter amendment giving the Board discretion to implement a reverse stock split at any ratio within a wide range (1-for-2 up to 1-for-99), to be chosen by the Board within approximately a year if approved. Management says the split is primarily to help the Company regain compliance with Nasdaq’s $1.00 minimum bid price and to enable financing and strategic options — the Board may nevertheless elect not to implement any split even if authorized. The measure is framed as a compliance and optionality tool, not an immediate execution directive. A nuanced analysis for sophisticated stakeholders should note three tensions: (1) the split can help avoid delisting and may attract certain institutional investors and improve perception, but it may also reduce liquidity and produce odd‑lot holdings and administrative frictions; (2) if implemented at a high ratio the split substantially increases the number of authorized but unissued shares as a percentage of outstanding shares (unless the authorized share count is reduced), enabling future dilution without further shareholder approval and potentially creating antitakeover effects; and (3) shareholders should consider the Board’s discretion, the breadth of the ratio range (which allows tailoring to market conditions but also gives management maximal latitude), and interdependencies with other proposals (notably the Preferred Stock conversions and the proposed increase in authorization) before voting. The Board recommends approval, arguing this maintains Nasdaq listing and provides strategic flexibility; opponents will stress dilution risk, anti-takeover effects and uncertain effects on liquidity and market cap.
- 7
Authorized Stock Increase Proposal
ManagementBoard: FORApprove amendment to the Certificate to increase authorized shares of Common Stock from 500,000,000 to up to 1,000,000,000 at Board discretion.
More detail
This proposal asks shareholders to authorize an amendment to increase the Company's authorized common shares from 500 million to up to 1.0 billion. Management says the increase is required by the Securities Purchase Agreement with investor David Lazar and would provide flexibility to issue shares for (1) conversions of Preferred Stock sold to Lazar, (2) equity awards, (3) financing or acquisition currency, and (4) other corporate purposes. The board recommends the increase. A sophisticated evaluation should note that the proposal is materially dilutive in potential (the Preferred Stock conversions alone could generate hundreds of millions of shares) and gives the board broad discretion to issue additional shares — which could accelerate dilution absent further shareholder approvals depending on exchange listing rules. Supporters will emphasize the practical financing and strategic flexibility the additional authorized shares enable. Opponents will emphasize long-term dilution risk and potential governance effects from concentrated issuances that the board could approve without further shareholder consent, especially given the concurrent investment transaction that concentrates control in a new investor. If you vote, evaluate the company’s disclosed pro forma capitalization, the conditionality of the Lazar financings, and whether the board’s discretion is balanced by disclosure and safeguards in the transaction documents.
- 8
Adjournment Proposal
ManagementBoard: FORApprove adjournment of the Special Meeting to solicit additional votes in the event there are insufficient votes to approve the proposals.
More detail
This is a standard management precautionary proposal that authorizes the chairman and proxies to adjourn the special meeting to solicit more votes if any proposals, particularly the Asset Sale or the Nasdaq approvals, lack sufficient support at the time of the meeting. Approving this empowers the Board to obtain the required votes without immediately losing the ability to transact if a vote falls short by allowing additional outreach. The board recommends approval. Analytically, adjournment authority benefits proponents when close outcomes exist, but it gives management time to persuade dissenters — which some investors may view as potentially coercive. If you are undecided, note that adjournment is used widely and does not change the underlying proposals; it only permits more time to solicit votes.
Nominees on the ballot2
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 1.2% | 223,030 | $294K |
| 2 | BlackRock, Inc. | 0.4% | 72,289 | $95K |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 0.3% | 57,751 | $76K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 0.3% | 57,047 | $75K |
| 5 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.3% | 52,500 | $69K |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.3% | 47,818 | $63K |
| 7 | JANE STREET GROUP, LLC | 0.2% | 34,118 | $45K |
| 8 | XTX Topco Ltd | 0.2% | 31,280 | $41K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 0.1% | 25,994 | $34K |
| 10 | STATE STREET CORP | 0.1% | 24,007 | $32K |
Other Consumer Cyclical sector meetings6
Upcoming shareholder meetings at Aterian Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Aterian Inc 2026 special meeting?
- Aterian Inc (ATER) holds its 2026 special shareholder meeting on Friday, July 10, 2026.
- What is the record date for the Aterian Inc 2026 meeting?
- The record date for the Aterian Inc 2026 meeting is Friday, May 29, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Aterian Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Aterian Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Aterian Inc 2026 meeting?
- Shareholders will vote on 8 proposals at the Aterian Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.